Vaxcyte's Drug Update Pushes 2 Biotech Stocks Lower
Vaxcyte Inc (NASDAQ:PCVX) stock is surging today, after the biotechnology company announced positive study results for its drug designed to prevent invasive pneumococcal disease in adults aged 50 or older.
Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine
Vaxcyte's shares surged more than 30% on Tuesday after the vaccine developer said its experimental pneumococcal vaccine showed promising results in an early-stage study, with a safety profile similar to rival Pfizer's shot.
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
Vaxcyte shares rocketed Tuesday after the biotech company delivered "stunning" test results for its pneumococcal vaccine.
Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine
Vaxcyte Inc.'s stock soared 33% early Tuesday, after the vaccine maker reported positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine candidate in adults aged 50 and older.
Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
The consensus price target hints at a 25.2% upside potential for Vaxcyte (PCVX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice
Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
